Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EZHiSWITCH: Valemetostat in Solid Tumors with SWI/SNF Alterations
NCT07303387Phase 2Recruiting
- Sponsor
- Gustave Roussy
- Start
- Mar 2026
- Primary completion
- Feb 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of valemetostat in solid tumor, clear cell endometrial carcinoma (CCEC), ovarian cancer, sponsored by Gustave Roussy. Started Mar 2026; status: recruiting.
02
Drugs
valemetostat
03
Conditions
solid tumorclear cell endometrial carcinoma (CCEC)ovarian cancer
Beyond the preview
Go deeper on NCT07303387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07303387.